



Zosano Pharma
Investor Relations Department
34790 Ardentech Ct.
Fremont, CA 94555
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ZSAN

Last Trade: 0.77

Trade Time: 1:12 PM ET
Oct 23, 2017

Change: -0.08 (-9.577%)

Day Range 0.76 - 0.85

52-Week Range 0.45 - 3.54

Volume 1,168,895

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Zosano Pharma is an emerging CNS company focusing on providing rapid symptom relief to patients, using known therapeutics with well-established safety and efficacy, but altering their delivery profile using the Company's proprietary transdermal delivery system. The Company's goal is to make transdermal drug delivery a standard of care for delivering drugs requiring fast onset of action.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Oct 20, 2017

[Zosano Enters into Common Stock Purchase Agreement with Lincoln Park Capital](#)

Oct 12, 2017

[Zosano Announces Publication of Pivotal Data of ADAM Zolmitriptan for the Acute Treatment of Migraine in Cephalalgia](#)

Oct 4, 2017

[Zosano Appoints Kenneth Greathouse to Board of Directors](#)

Sep 26, 2017

[Zosano Provides Patent Application Update](#)

Sep 13, 2017

[Zosano Presents Data from ZOTRIP Study at International Headache Society](#)

Financials [\[View all \]](#)

Mar 1, 2017

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 10, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)

Nov 9, 2016

[Quarterly Report \(10-Q\)](#)